Insmed Trading Volume Soars 132.7% to 2.47 Billion, Ranked 377th Despite Stock Price Decline

On April 24, 2025, Insmed's trading volume reached 2.47 billion, marking a significant increase of 132.7% compared to the previous day. This placed insmed at the 377th position in terms of trading volume for the day. However, the stock price of Insmed (INSM) experienced a decline of 2.60%, marking the second consecutive day of decrease, with a total drop of 3.20% over the past two days.

Insmed Incorporated, a biopharmaceutical company, has recently announced that it has received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding its New Drug Application (NDA) for its drug candidate, brensocatib. The CRL indicates that the FDA is unable to approve the NDA in its current form, citing the need for additional clinical data to support the drug's efficacy and safety. Insmed has stated that it is currently evaluating the CRL and will work with the FDA to address the concerns raised.

In response to the CRL, Insmed's stock price has experienced volatility, reflecting investor concerns about the regulatory hurdles facing the company's drug candidate. The company's management has emphasized its commitment to advancing brensocatib through the regulatory process and has expressed confidence in the drug's potential to address unmet medical needs. Insmed is expected to provide further updates on its plans to address the FDA's concerns in the coming weeks.

Ask Aime: "Has Insmed received FDA approval for brensocatib, and if not, what's next?"